Delray Beach, FL, Aug. 20, 2025 (GLOBE NEWSWIRE) — The global AI in remote patient monitoring market, valued at US$1551.8 million in 2023, stood at US$1,967.7 million in 2024 and is projected to advance at a resilient CAGR of 27.5% from 2024 to 2030, culminating in a forecasted valuation of US$8,438.5 million by the end of the period. This unprecedented growth underscores how AI-driven health technologies are reshaping patient care, reducing costs, and addressing workforce challenges across health systems worldwide.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82144961
What is Driving Market Growth?
The acceleration is fueled by the expansion of telehealth services, greater accessibility to healthcare, and favorable reimbursement policies. Supportive legislation, such as the Telehealth Modernization Act in the U.S. and the European Health Data Space (EHDS) regulation adopted on January 21, 2025, has further strengthened the foundation for seamless cross-border healthcare and virtual care integration.
Governments from the U.S. to India and the U.K. are advancing digital health strategies. For example, India’s National Digital Health Mission and the U.K.’s NHS digital ecosystem are integrating AI to enable scalable RPM, while the Biden Administration has mandated oversight of AI-enabled medical devices through the FDA.
Why Does This Matter Now?
With rising chronic disease burdens and limited hospital capacities, AI-enabled RPM allows healthcare providers to detect conditions earlier, manage patients remotely, and avoid unnecessary hospitalizations. This technology is particularly impactful in acute care, behavioral health, and chronic disease management. The Centers for Medicare & Medicaid Services (CMS) has extended reimbursement for AI-assisted RPM, broadening adoption for both acute and chronic care.
Market Dynamics: Opportunities and Challenges
- Drivers: Rapid adoption of wearable devices, integration of AI analytics, and the proliferation of telehealth apps. As of March 2023, 34 U.S. state Medicaid programs covered RPM, while the FDA has already cleared 75 AI/ML-enabled diagnostic tools.
- Restraints: Regulatory inconsistencies across geographies, including diverging definitions of medical devices between the EU MDR and the U.S. FD&C Act, continue to challenge …